ArrowMark Colorado Holdings LLC Has $10.36 Million Holdings in CG Oncology, Inc. $CGON

ArrowMark Colorado Holdings LLC cut its position in CG Oncology, Inc. (NASDAQ:CGON) by 12.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 257,230 shares of the company’s stock after selling 35,776 shares during the quarter. ArrowMark Colorado Holdings LLC owned about 0.34% of CG Oncology worth $10,361,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Candriam S.C.A. raised its holdings in CG Oncology by 35.9% in the 3rd quarter. Candriam S.C.A. now owns 1,037,892 shares of the company’s stock valued at $41,806,000 after acquiring an additional 274,312 shares during the period. Voya Investment Management LLC boosted its holdings in shares of CG Oncology by 217.6% during the third quarter. Voya Investment Management LLC now owns 47,986 shares of the company’s stock worth $1,933,000 after acquiring an additional 32,877 shares during the period. Vanguard Group Inc. grew its position in shares of CG Oncology by 11.4% in the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after purchasing an additional 670,770 shares during the last quarter. Mangrove Partners IM LLC grew its position in shares of CG Oncology by 21.0% in the third quarter. Mangrove Partners IM LLC now owns 671,692 shares of the company’s stock valued at $27,056,000 after purchasing an additional 116,575 shares during the last quarter. Finally, Tejara Capital Ltd bought a new position in shares of CG Oncology during the second quarter worth approximately $944,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CG Oncology Price Performance

Shares of NASDAQ:CGON opened at $64.29 on Monday. The company has a market capitalization of $5.43 billion, a P/E ratio of -31.06 and a beta of 1.17. The business’s 50 day simple moving average is $54.66 and its 200 day simple moving average is $44.83. CG Oncology, Inc. has a 1 year low of $14.80 and a 1 year high of $64.70.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The company had revenue of $2.32 million for the quarter. On average, sell-side analysts anticipate that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on CGON shares. Wedbush initiated coverage on CG Oncology in a report on Thursday, December 11th. They set an “outperform” rating and a $70.00 price target for the company. Piper Sandler increased their price objective on CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Morgan Stanley set a $93.00 target price on shares of CG Oncology in a research report on Friday, January 9th. Finally, Royal Bank Of Canada upped their price target on shares of CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, CG Oncology currently has an average rating of “Moderate Buy” and an average price target of $69.00.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.